CPCRA Clinical Trials Unit

CPRA 临床试验单位

• 批准号: 8416421
• 负责人: Fred M Gordin
• 金额: $ 419.57万
• 依托单位: GEORGE WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-06-15 至 2013-12-09
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8416421
• 关键词: AIDS/HIV problem; Acquired Immunodeficiency Syndrome; Affect; Anti-Retroviral Agents; Behavior Therapy; Behavioral; Brazil; Canada; Cardiovascular Diseases; Caring; Clinical Management; Clinical Research; Clinical Trials; Clinical Trials Unit; Cocaine Users; Collaborations; Communities; Disease; District of Columbia; Enrollment; HIV; HIV Infections; HIV prevention trial; HIV prevention trials network; Hepatitis Viruses; Individual; Infection; Injecting drug user; Institution; Life; Medical center; Medicine; Opportunistic Infections; Outcome; Patients; Persons; Peru; Population Heterogeneity; Prevention; Principal Investigator; Public Health; Randomized Clinical Trials; Research; Risk; Risk Behaviors; Site; South Africa; Target Populations; Therapeutic Intervention; Training and Education; United States; Universities; Veterans; Washington; base; clinically relevant; experience; high risk; member; programs; transmission process

DESCRIPTION (provided by applicant): The objectives of the CPCRA Clinical Trials Unit (Community Programs for Clinical Research on AIDS) are: to conduct clinically relevant research in the prevention and treatment of HIV disease and its complications; to involve in clinical trials a demographically, geographically, and socio-economically diverse population of individuals infected with HIV or at risk of infection; and to carry out this research agenda in close collaboration with community members who are themselves infected with or affected by HIV. The CPCRA CTU will make significant contributions to the INSIGHT and HIV Prevention Trials (HPTN) networks, both in enrollment and in scientific expertise. Through INSIGHT, the CPCRA CTU will contribute to multiple, randomized clinical trials in order to help determine the optimal clinical management for persons who are HIV+. These trials include studies of those who are: highly-antiretroviral (ARV) experienced and for whom virologic suppression cannot be achieved and maintained; ARV-naive, with advanced HIV disease and presenting for care with an opportunistic infection; co-infected with HIV and hepatitis virus; or at moderate-to-high risk of cardiovascular disease. Through the HPTN, the CPCRA CTU will contribute to trials examining both behavioral and therapeutic interventions with behavioral and biologic outcomes, seeking to reduce HIV transmission and HIV transmission-risk behavior. Targeted populations include those who are HIV+, as well as those who are HIV- and at-risk for seroconversion, such as injecting-drug and cocaine users and others at risk for seroconversion through sexual contact. The Executive Office of the CPCRA Clinical Trials Unit, located at the Veterans Affairs Medical Center in Washington DC, is an off-campus affiliate of the applicant institution, The George Washington University. The Principal Investigator and Executive Office staff provide oversight, central coordination, training and education, technical assistance, and regulatory support for its 137 CRSs, organized by region into 23 Site Coordinating Centers (SCCs) in the United States, Brazil, Canada, Peru, and South Africa. These sites have in care a cumulative, demographically diverse patient base of over 152,000 persons with HIV/AIDS. HIV is a major public health problem around the world. It is important to find better ways to use the medicines that we have to treat HIV, so that people who are infected can live longer and healthier lives. It is also important to find better ways to stop the spread of HIV by doing studies with people who have HIV infection and people who don't have HIV but who are at risk for getting HIV infection. ADMINISTRATIVE COMPONENT:

描述（由申请人提供）： CPCRA临床试验部门的目标（艾滋病临床研究社区计划）是：在预防和治疗艾滋病毒疾病及其并发症方面进行临床相关研究;让人口、地理和社会经济多样化的艾滋病毒感染者或有感染风险的人群参与临床试验;并与本身感染艾滋病毒或受艾滋病毒影响的社区成员密切合作，开展这一研究议程。 CPCRA CTU将为INSIGHT和HIV预防试验（HPTN）网络在招生和科学专业知识方面做出重大贡献。通过INSIGHT，CPCRA CTU将为多项随机临床试验做出贡献，以帮助确定艾滋病毒阳性者的最佳临床管理。这些试验包括对以下人群的研究：高度抗逆转录病毒（ARV）经验丰富且无法实现和维持病毒学抑制的患者;未接受过ARV治疗、患有晚期艾滋病毒疾病并因机会性感染而需要治疗的患者;合并感染艾滋病毒和肝炎病毒的患者;或心血管疾病中高风险患者。通过HPTN，CPCRA CTU将有助于研究行为和治疗干预与行为和生物学结果的试验，寻求减少艾滋病毒传播和艾滋病毒传播风险行为。目标人群包括艾滋病毒阳性者以及艾滋病毒阳性和有血清转化风险的人，如注射毒品和可卡因使用者以及其他有通过性接触发生血清转化风险的人。 CPCRA临床试验部门的执行办公室位于华盛顿特区的退伍军人事务医疗中心，是申请机构乔治华盛顿大学的校外附属机构。主要研究者和执行办公室工作人员为其137个CRS提供监督、中央协调、培训和教育、技术援助和监管支持，这些CRS按地区分为美国、巴西、加拿大、秘鲁和南非的23个研究中心协调中心（SCC）。在这些医疗点接受治疗的患者人数累计超过152 000名，而且患者的人口构成各不相同。 艾滋病毒是全世界的一个重大公共卫生问题。重要的是要找到更好的方法来使用我们治疗艾滋病毒的药物，以便感染者能够活得更长和更健康。同样重要的是找到更好的方法来阻止艾滋病毒的传播，对艾滋病毒感染者和没有艾滋病毒但有感染艾滋病毒风险的人进行研究。 行政部门：

项目成果

Identifying Spatial Variation Along the HIV Care Continuum: The Role of Distance to Care on Retention and Viral Suppression.

识别沿HIV护理连续体的空间变异：护理在保留和病毒抑制中的作用。

• DOI: 10.1007/s10461-018-2103-8
• 发表时间: 2018-09
• 期刊: AIDS and behavior
• 影响因子: 4.4
• 作者: Terzian AS;Younes N;Greenberg AE;Opoku J;Hubbard J;Happ LP;Kumar P;Jones RR;Castel AD;DC Cohort Executive Committee
• 通讯作者: DC Cohort Executive Committee

Biomarkers of immune dysfunction in HIV.

• DOI: 10.1097/coh.0b013e32833ed6f4
• 发表时间: 2010-11
• 期刊: Current opinion in HIV and AIDS
• 影响因子: 4.1
• 作者: Nixon DE;Landay AL
• 通讯作者: Landay AL

Sexually Transmitted Infections Among HIV-Infected Individuals in the District of Columbia and Estimated HIV Transmission Risk: Data From the DC Cohort.

• DOI: 10.1093/ofid/ofy017
• 发表时间: 2018-03
• 期刊: Open forum infectious diseases
• 影响因子: 4.2
• 作者: Lucar J;Hart R;Rayeed N;Terzian A;Weintrob A;Siegel M;Parenti DM;Squires LE;Williams R;Castel AD;Benator DA;DC Cohort Executive Committee
• 通讯作者: DC Cohort Executive Committee

Disparities in achieving and sustaining viral suppression among a large cohort of HIV-infected persons in care - Washington, DC.

• DOI: 10.1080/09540121.2016.1189496
• 发表时间: 2016-11
• 期刊: AIDS care
• 影响因子: 1.7
• 作者: Castel AD;Kalmin MM;Hart RL;Young HA;Hays H;Benator D;Kumar P;Elion R;Parenti D;Ruiz ME;Wood A;D'Angelo L;Rakhmanina N;Rana S;Bryant M;Hebou A;Fernández R;Abbott S;Peterson J;Wood K;Subramanian T;Binkley J;Happ LP;Kharfen M;Masur H;Greenberg AE
• 通讯作者: Greenberg AE